Chris Easley
Head of Market Access Solutions
Pope Woodhead and Associates Ltd.
Mason W. Russell
Vice President, Strategic Consulting (Life Sciences)
Truven, USA
Janice Haigh
Vice President, Pricing & Market Access
PAREXEL
Santanu Das
Vice President
GFK, UK
Most developed countries apply some form of IRP as a factor in negotiating or regulating domestic pricing. With the emergence of risk sharing agreements and in particular confidential price / volume agreements tied to HTA assessments some experts are suggesting the end of IRP systems in imminent. In contrast, some countries like Canada are placing greater reliance on IRP to lower drug prices.
Neil Palmer
Founder & Senior Consultant
PDCI Market Access
Giles Thurston
Head of Digital Solutions
Pope Woodhead and Associates Ltd.
Anke van Engen
Principal, Consulting Services
QuintilesIMS
Finn Boerlum Kristensen
Managing Director Science & Policy, Faculty of Health Sciences, University of Southern Denmark
Former EUnetHTA Executive, Committee Chairman and EUnetHTA Secretariat Director